129 related articles for article (PubMed ID: 16870436)
1. Synthesis and biological activity of 5-aryl-4-(4-(5-methyl-1H-imidazol-4-yl)piperidin-1-yl)pyrimidine analogs as potent, highly selective, and orally bioavailable NHE-1 inhibitors.
Atwal KS; O'Neil SV; Ahmad S; Doweyko L; Kirby M; Dorso CR; Chandrasena G; Chen BC; Zhao R; Zahler R
Bioorg Med Chem Lett; 2006 Sep; 16(18):4796-9. PubMed ID: 16870436
[TBL] [Abstract][Full Text] [Related]
2. Piperazine-based CCR5 antagonists as HIV-1 inhibitors. IV. Discovery of 1-[(4,6-dimethyl-5-pyrimidinyl)carbonyl]- 4-[4-[2-methoxy-1(R)-4-(trifluoromethyl)phenyl]ethyl-3(S)-methyl-1-piperazinyl]- 4-methylpiperidine (Sch-417690/Sch-D), a potent, highly selective, and orally bioavailable CCR5 antagonist.
Tagat JR; McCombie SW; Nazareno D; Labroli MA; Xiao Y; Steensma RW; Strizki JM; Baroudy BM; Cox K; Lachowicz J; Varty G; Watkins R
J Med Chem; 2004 May; 47(10):2405-8. PubMed ID: 15115380
[TBL] [Abstract][Full Text] [Related]
3. Discovery of 1-(3'-aminobenzisoxazol-5'-yl)-3-trifluoromethyl-N-[2-fluoro-4- [(2'-dimethylaminomethyl)imidazol-1-yl]phenyl]-1H-pyrazole-5-carboxyamide hydrochloride (razaxaban), a highly potent, selective, and orally bioavailable factor Xa inhibitor.
Quan ML; Lam PY; Han Q; Pinto DJ; He MY; Li R; Ellis CD; Clark CG; Teleha CA; Sun JH; Alexander RS; Bai S; Luettgen JM; Knabb RM; Wong PC; Wexler RR
J Med Chem; 2005 Mar; 48(6):1729-44. PubMed ID: 15771420
[TBL] [Abstract][Full Text] [Related]
4. A novel class of sodium/calcium exchanger inhibitors: design, synthesis, and structure-activity relationships of 4-phenyl-3-(piperidin-4-yl)-3,4-dihydro-2(1H)-quinazolinone derivatives.
Hasegawa H; Muraoka M; Matsui K; Kojima A
Bioorg Med Chem Lett; 2006 Feb; 16(3):727-30. PubMed ID: 16249082
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, and biological activity of 4-[(4-cyano-2-arylbenzyloxy)-(3-methyl-3H-imidazol-4-yl)methyl]benzonitriles as potent and selective farnesyltransferase inhibitors.
Wang L; Wang GT; Wang X; Tong Y; Sullivan G; Park D; Leonard NM; Li Q; Cohen J; Gu WZ; Zhang H; Bauch JL; Jakob CG; Hutchins CW; Stoll VS; Marsh K; Rosenberg SH; Sham HL; Lin NH
J Med Chem; 2004 Jan; 47(3):612-26. PubMed ID: 14736242
[TBL] [Abstract][Full Text] [Related]
6. (2-Methyl-5-(methylsulfonyl)benzoyl)guanidine Na+/H+ antiporter inhibitors.
Baumgarth M; Beier N; Gericke R
J Med Chem; 1997 Jun; 40(13):2017-34. PubMed ID: 9207943
[TBL] [Abstract][Full Text] [Related]
7. Design of 2,5-dimethyl-3-(6-dimethyl-4-methylpyridin-3-yl)-7-dipropylaminopyrazolo[1,5-a]pyrimidine (NBI 30775/R121919) and structure--activity relationships of a series of potent and orally active corticotropin-releasing factor receptor antagonists.
Chen C; Wilcoxen KM; Huang CQ; Xie YF; McCarthy JR; Webb TR; Zhu YF; Saunders J; Liu XJ; Chen TK; Bozigian H; Grigoriadis DE
J Med Chem; 2004 Sep; 47(19):4787-98. PubMed ID: 15341493
[TBL] [Abstract][Full Text] [Related]
8. Antagonists of human CCR5 receptor containing 4-(pyrazolyl)piperidine side chains. Part 2: Discovery of potent, selective, and orally bioavailable compounds.
Shen DM; Shu M; Willoughby CA; Shah S; Lynch CL; Hale JJ; Mills SG; Chapman KT; Malkowitz L; Springer MS; Gould SL; DeMartino JA; Siciliano SJ; Lyons K; Pivnichny JV; Kwei GY; Carella A; Carver G; Holmes K; Schleif WA; Danzeisen R; Hazuda D; Kessler J; Lineberger J; Miller MD; Emini EA
Bioorg Med Chem Lett; 2004 Feb; 14(4):941-5. PubMed ID: 15012998
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and biological evaluation of 5-[(aryl)(1H-imidazol-1-yl)methyl]-1H-indoles: potent and selective aromatase inhibitors.
Lézé MP; Le Borgne M; Pinson P; Palusczak A; Duflos M; Le Baut G; Hartmann RW
Bioorg Med Chem Lett; 2006 Mar; 16(5):1134-7. PubMed ID: 16380254
[TBL] [Abstract][Full Text] [Related]
10. Discovery of an N-(2-aminopyridin-4-ylmethyl)nicotinamide derivative: a potent and orally bioavailable NCX inhibitor.
Kuramochi T; Kakefuda A; Yamada H; Tsukamoto I; Taguchi T; Sakamoto S
Bioorg Med Chem; 2005 Jun; 13(12):4022-36. PubMed ID: 15911315
[TBL] [Abstract][Full Text] [Related]
11. 4-[5-Fluoro-3-[4-(2-methyl-1H-imidazol-1-yl)benzyloxy]phenyl]-3,4,5,6- tetrahydro-2H-pyran-4-carboxamide, an orally active inhibitor of 5-lipoxygenase with improved pharmacokinetic and toxicology characteristics.
Mano T; Okumura Y; Sakakibara M; Okumura T; Tamura T; Miyamoto K; Stevens RW
J Med Chem; 2004 Jan; 47(3):720-5. PubMed ID: 14736252
[TBL] [Abstract][Full Text] [Related]
12. Structure-activity relationship of heterobase-modified 2'-C-methyl ribonucleosides as inhibitors of hepatitis C virus RNA replication.
Eldrup AB; Prhavc M; Brooks J; Bhat B; Prakash TP; Song Q; Bera S; Bhat N; Dande P; Cook PD; Bennett CF; Carroll SS; Ball RG; Bosserman M; Burlein C; Colwell LF; Fay JF; Flores OA; Getty K; LaFemina RL; Leone J; MacCoss M; McMasters DR; Tomassini JE; Von Langen D; Wolanski B; Olsen DB
J Med Chem; 2004 Oct; 47(21):5284-97. PubMed ID: 15456273
[TBL] [Abstract][Full Text] [Related]
13. Discovery of S-[5-amino-1-(4-fluorophenyl)-1H-pyrazol-4-yl]-[3-(2,3-dihydroxypropoxy)phenyl]methanone (RO3201195), an orally bioavailable and highly selective inhibitor of p38 MAP kinase.
Goldstein DM; Alfredson T; Bertrand J; Browner MF; Clifford K; Dalrymple SA; Dunn J; Freire-Moar J; Harris S; Labadie SS; La Fargue J; Lapierre JM; Larrabee S; Li F; Papp E; McWeeney D; Ramesha C; Roberts R; Rotstein D; San Pablo B; Sjogren EB; So OY; Talamas FX; Tao W; Trejo A; Villasenor A; Welch M; Welch T; Weller P; Whiteley PE; Young K; Zipfel S
J Med Chem; 2006 Mar; 49(5):1562-75. PubMed ID: 16509574
[TBL] [Abstract][Full Text] [Related]
14. The synthesis and biological evaluation of dopamine transporter inhibiting activity of substituted diphenylmethoxypiperidines.
Lapa GB; Byrd GD; Lapa AA; Budygin EA; Childers SR; Jones SR; Harp JJ
Bioorg Med Chem Lett; 2005 Nov; 15(22):4915-8. PubMed ID: 16165350
[TBL] [Abstract][Full Text] [Related]
15. Imidazo[1,2-a]pyrimidines as functionally selective and orally bioavailable GABA(A)alpha2/alpha3 binding site agonists for the treatment of anxiety disorders.
Goodacre SC; Street LJ; Hallett DJ; Crawforth JM; Kelly S; Owens AP; Blackaby WP; Lewis RT; Stanley J; Smith AJ; Ferris P; Sohal B; Cook SM; Pike A; Brown N; Wafford KA; Marshall G; Castro JL; Atack JR
J Med Chem; 2006 Jan; 49(1):35-8. PubMed ID: 16392789
[TBL] [Abstract][Full Text] [Related]
16. Modulators of the human CCR5 receptor. Part 2: SAR of substituted 1-(3,3-diphenylpropyl)-piperidinyl phenylacetamides.
Cumming JG; Cooper AE; Grime K; Logan CJ; McLaughlin S; Oldfield J; Shaw JS; Tucker H; Winter J; Whittaker D
Bioorg Med Chem Lett; 2005 Nov; 15(22):5012-5. PubMed ID: 16154744
[TBL] [Abstract][Full Text] [Related]
17. Nonpeptide oxytocin antagonists: potent, orally bioavailable analogs of L-371,257 containing a 1-R-(pyridyl)ethyl ether terminus.
Kuo MS; Bock MG; Freidinger RM; Guidotti MT; Lis EV; Pawluczyk JM; Perlow DS; Pettibone DJ; Quigley AG; Reiss DR; Williams PD; Woyden CJ
Bioorg Med Chem Lett; 1998 Nov; 8(21):3081-6. PubMed ID: 9873680
[TBL] [Abstract][Full Text] [Related]
18. 3-[3-Fluoro-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)phenyl]-4-methylpyridine: a highly potent and orally bioavailable metabotropic glutamate subtype 5 (mGlu5) receptor antagonist.
Poon SF; Eastman BW; Chapman DF; Chung J; Cramer M; Holtz G; Cosford ND; Smith ND
Bioorg Med Chem Lett; 2004 Nov; 14(22):5477-80. PubMed ID: 15482907
[TBL] [Abstract][Full Text] [Related]
19. Development of orally bioavailable bicyclic pyrazolones as inhibitors of tumor necrosis factor-alpha production.
Clark MP; Laughlin SK; Laufersweiler MJ; Bookland RG; Brugel TA; Golebiowski A; Sabat MP; Townes JA; VanRens JC; Djung JF; Natchus MG; De B; Hsieh LC; Xu SC; Walter RL; Mekel MJ; Heitmeyer SA; Brown KK; Juergens K; Taiwo YO; Janusz MJ
J Med Chem; 2004 May; 47(11):2724-7. PubMed ID: 15139749
[TBL] [Abstract][Full Text] [Related]
20. Fluorination of 3-(3-(piperidin-1-yl)propyl)indoles and 3-(3-(piperazin-1-yl)propyl)indoles gives selective human 5-HT1D receptor ligands with improved pharmacokinetic profiles.
van Niel MB; Collins I; Beer MS; Broughton HB; Cheng SK; Goodacre SC; Heald A; Locker KL; MacLeod AM; Morrison D; Moyes CR; O'Connor D; Pike A; Rowley M; Russell MG; Sohal B; Stanton JA; Thomas S; Verrier H; Watt AP; Castro JL
J Med Chem; 1999 Jun; 42(12):2087-104. PubMed ID: 10377215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
